Rentschler Appoints New Chief Business Officer
News Mar 08, 2013
Rentschler Biotechnologie GmbH has announced the appointment of Frank Ternes to the position of Chief Business Officer effective February 1, 2013.
In this position, Mr. Ternes will contribute to the success of the organization by leading the planning, development and execution of all business development, sales & marketing and project management activities.
"Mr. Ternes is an excellent addition to Rentschler's management board," says Dr. Nikolaus F. Rentschler, CEO and owner of Rentschler.
Dr. Rentschler continued, "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”
Frank Ternes brings more than 25 years of experience from Operations and Technology at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing.
Mr. Ternes holds a degree equivalent to a master’s degree in economics from the University of Bonn, Germany.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.